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Targeted drugs tailored against genes and signaling proteins have formed the new era termed Targeted Therapies. Although the
ﬁeld is relatively young, since only about 5 years ago clinical trials started showing promise, there have are already been signiﬁcant
setbacks due to drug resistance caused by point mutations, alterations in gene expression or complete loss of target proteins with
disease progression. Although new drugs are continuously designed and tried, it seems inevitable that genetic and signal protein
targets pose too broad ﬂexibility and variability, often changing target characteristics and thus escape treatments turning ‘‘magic
bullets’’ into rather ‘‘wondering bullets’’. This is especially true in cancer, where old and new targeted therapies continue to fail and
the most recent ones do not offer much improvement on clinical outcome parameters. Metabolic targeted therapies are aimed at
control points of the metabolic network by targeting particular enzymes of major macromolecule synthesis pathways in cancer.
This review summarizes the potential beneﬁts of targeted therapies in the metabolic network as applied with genetic and proteomic
approaches. The metabolic target approach is most efﬁcient if and when pathway ﬂux information is available for drug target
development using the stable isotope based dynamic metabolic proﬁle (SIDMAP) of tumor cells, in vitro or in vivo.
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1. Introduction
Tumor cells inherently possess various mechanisms
to initiate and sustain any one of the following
phenotypes: 1. proliferative; 2. diﬀerentiated; 3. trans-
formed; 4. cycle arrested; 5. necrotic; and 6. apoptotic
(Boros et al., 2002a). Advanced and therapy resistant
tumors share one common phenotype characterized by
rapid proliferation, poor diﬀerentiation – increased
transformation, as well as multiple drug and apoptosis
resistance. They also exhibit a high rate of metabolism
using glucose as the primary substrate (Pitot and Jost,
1967; Schwartz et al., 1986; Boekhorst et al., 1995;
Smith, 1998). Therefore, it is likely that tumor cells’
sensitivity to exogenous and endogenous factors
determining growth and diﬀerentiation is deeply hidden
in the metabolic network supplying essential substrates
for de novo macromolecule synthesis and energy pro-
duction. The rate of proliferation is closely associated
with the rate of de novo macromolecule synthesis, such
as RNA, DNA, amino acids and fatty acids (Eigen-
brodt et al., 1992). These complex molecules, which
eventually become structural components of new and
old progenies of tumor cells, are synthesized from
small molecular weight substrates, such as glucose,
short chain fatty acids and amino acids in an inter-
connected and complex metabolic network. All path-
ways in the network depend on one another via
substrate sharing and channeling, and by regenerating
shared co-factors that participate in oxidative degra-
dation and reductive synthesis simultaneously. Such
relationship is evident between direct glucose oxidation
in the pentose cycle and de novo fatty acid synthesis,
where part of the reduced NADP+ pool is regenerated
allowing the irreversible glucose-6-phosphate dehydro-
genase reaction to proceed for the synthesis of ﬁve
carbon sugars (Kuhajda, 2000; Baron et al., 2004). In
turn, the reducing NADP+ equivalent is used during
reductive de novo synthesis of fatty acids, their chain
elongation and de-saturation, allowing distant meta-
bolic network processes to proceed in a well-controlled
and synchronized fashion. Cell phenotypes and their
sensitivity to apoptosis, which is the focus of this re-
view; demonstrate diﬀerences in their respective stable
isotope-labeled dynamic metabolic proﬁles (SIDMAP)
of cross-regulated metabolic pathways in the network.
The models discussed herein include therapy resistant
inﬂammatory breast cancer cells in comparison with
apoptosis sensitive human ﬁbroblasts and therapy
sensitive pancreatic tumor cells. I herein argue that
targeted therapies of the metabolic network may
overcome diﬃculties of drug design related to the
enormous variability of the ever changing pool of genetic
and proteomic targets in cancer (Hu and Kavanagh, 2003;
Cowan-Jacob et al., 2004; Shah et al., 2004; Guillemard
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and Saragovi, 2004). However, one has to ﬁrst learn how
to trace and read the map of the uniquely altered meta-
bolic network of tumor cells in order to design new tar-
geted therapies within.
2. Targeted therapies of cancer using genetic and
proteomic targets
Targeted drugs are designed for a single or a very
narrow range of genetic or protein targets. Although
they are extremely eﬀective to treat narrow cancer cell
populations with a very favorable low toxicity proﬁle
towards the host, their main limitations are high
dependence on a single highly modiﬁable target and the
rapid development of resistance based on four major
mechanisms: 1. decrease in target protein expression;
2. mutations in target proteins; 3. loss of target gene
and/or construct due to clonal selection; and 4. in-
creased drug transport from targeted cells. These
limitations have produced signiﬁcant delays, cost accu-
mulations or disappointments with almost all targeted
drugs designed so far.
3. Eﬀorts in targeted drug design against genetic and
protein targets in cancer
Targeted therapies have continuously been devel-
oped and explored for the treatment of human cancer.
Monoclonal antibodies, for example epidermal growth
factor monoclonal antibodies (EGF mABs), and small
molecule receptor antagonists have oﬀered high speci-
ﬁcity against cytokines and cell surface receptors to
inhibit growth signaling. The main challenges are host
immune response and increased cytokine production,
leading to low response rate especially in advanced
refractory cancers (Dancey and Freidlin, 2003).
Another approach is to conjugate toxins or radioisotopes
for the treatment of leukemia, which oﬀers targeted
delivery of high eﬃcacy drugs. The delivery of these
toxic agents is ligand dependent and therefore in clinical
trials low response rate and recurrence still pose chal-
lenges (Sievers, 2000; Nemecek and Matthews, 2003).
Antisense oligonucleotides are gene expression modify-
ing short nucleic acid sequences, where the delivery
system is still not resolved because of severe host re-
sponse to viral vectors. The most severe side eﬀects are
hemolytic anemia, renal failure and delayed immune
reactions such as anasarca, which held up further clini-
cal tests (Rudin et al., 2001). Immunoliposome-encap-
sulated drugs are aimed for targeted delivery of
protected antibodies. Their main disadvantages are
moderate stability and the inability of the carrier to
extravasate, or to leave the circulatory system, leading
to low eﬃcacy and high failure rate in clinical trials
(Matzku et al., 1990). Small molecule inhibitors, such as
imatinib (STI-571), target single oncogenic protein
constructs, however recurrence with blast disease and
increasing drug resistance in chronic myeloid leukemia is
an emerging and severe problem (Hofmann et al., 2004).
It is evident that although the targeting of narrow
oncogenic constructs with ‘‘magic bullets’’ is an old
approach that raised high expectations, multiple mech-
anisms slipping the target continuously oﬀ site in the
ever changing genetic and proteomic maze of targets
make this approach ever more expensive and less eﬀec-
tive. One solution is to redesign drugs with altered
structure to hit a new target range (Shah et al., 2004),
but this approach is controversial, again, given the dif-
ﬁculties and costs involved in repeated clinical trials for
each new drug, targeting slightly mutated proteins or
increasing expression of genes. This will likely exhaust
research and development budgets of even large drug
companies on the long run, as the cost of targeted
therapy drug design is enormous, as compared to con-
ventional treatments, while the return is strenuous due
to narrow groups and limited number of patients who
beneﬁt from them. It is also evident that health insur-
ance companies will not be able to cover the ever
growing costs of targeted therapies, lasting for as long as
they would be necessary to keep the ever changing ge-
netic and protein proﬁles of tumor growth under control
(Danzon and Towse, 2002). Considering even a few
possible meaningful oncogenic permutations as expected
from gene and protein variations, targeted therapies
against the genetic and proteomic network may well be
the most expensive medicine has yet taken with little in
return regarding cancer disease outcome or improving
population health.
4. Metabolomics: the study of the transformed metabolic
network in cancer
Metabolomics is a new ﬁeld in medicine addressing
and developing platforms which presumably will achieve
better understanding and allowing more eﬀective drug
design against many human diseases, including cancer
(Schmidt, 2004). Metabolomics as a tool is designed
around quantitative metabolite level measurement and
ratios, which are mined typically, using several pattern
recognition techniques, including principal components
analysis and hierarchical cluster analysis. This combined
approach is being termed metabolomics and foresights
into the ﬁeld predict a strong competing role in medicine
to genetics and proteomics. While there is still important
reliance on functional genomics to further elucidate the
role of genes and their protein products in human can-
cer, there is also an increasing necessity to deﬁne and
understand how the genetic and protein networks
conspire with the metabolism of particular tumor
phenotypes (Griﬃn, 2004). Although it is known that
metabolic networks also vary in their substrate
utilization patterns and ﬂux distribution reﬂecting cell
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function and phenotype, their control points have
strictly been preserved throughout evolution and are
very reliable drug targets considering the limited number
of enzyme isoforms as well as the limited number of
major alternative metabolic routes, which are mostly
known. Metabolism is an old ﬁeld with new potentials
to assist drug development, although one has to ﬁrst
learn how to navigate among the many interconnected
pathways, how to trace and deﬁne targets, and how to
determine and utilize existing control among distant
metabolic pathways in the same network (Boros et al.,
2003c).
5. Stable isotope labeled metabolic network and
sensitivity to apoptosis
5.1. Apoptosis sensitive cells heavily depend on
non-oxidative pentose cycle metabolism while
lacking de novo fatty acid synthesis
The double tracer approach using stable isotope
labeled glucose is particularly eﬀective in revealing
detailed substrate ﬂow and distribution patterns in the
complex metabolic network of human cells. Applica-
tions in cancer have greatly assisted us to understand
growth controlling mechanisms in the transformed
network (Boros et al., 2002b, Boros 2003a). SIDMAP
has revealed that pentose cycle metabolism with lacking
de novo fatty acid synthesis makes human ﬁbroblasts
extremely vulnerable to apoptosis when thiamine, co-
factor of the transketolase non-oxidative pentose cycle
enzyme, becomes limited due to defective high aﬃnity
thiamine transport (Green 2003; Boros et al., 2003b).
Thiamine transport deﬁcient human ﬁbroblasts readily
undergo apoptosis in culture with no rescue mechanism
in place as they lack de novo fatty acid synthesis and
therefore posses limited reserves of the oxidized form of
NADP+, which is the sole hydrogen acceptor during
oxidative pentose synthesis from glucose in the cycle.
Similarly, pancreatic adenocarcinoma cells (MIA PaCa)
show limited growth and in response to pentose cycle
inhibitors (Boros et al., 1997) and possess a relatively
low rate (20%) de novo fatty acid synthesis and turnover
during the 72 h treatment period (Boros et al., 2001a,
2001b). Figure 1 demonstrates metabolic pathway sub-
strate ﬂow in apoptosis sensitive human cells using
doubly labeled glucose as the tracer.
5.2. Apoptosis resistant cells heavily depend on oxidative
pentose cycle metabolism by maintaining high rate
of de novo fatty acid synthesis and turnover
The SIDMAP of therapy and apoptosis resistant
tumor cells shown on ﬁgure 1 is diﬀerent from that of
therapy sensitive cells shown on Figure 2, which
illustrates the metabolic proﬁle of therapy resistant
inﬂammatory breast cancer cells indicating intense
tracer accumulation into fatty acids.
The main diﬀerence is the rate at which they syn-
thesize medium and long chain saturated fatty acids
up to the 16 carbon chain length palmitate and conse-
quently elongate it to the 18 carbon length stearate and
further into C:20–C:26 species. They also posses high
fatty acid chain desaturase activity, further oxidizing
NADPH and allowing the oxidative branch of the
pentose cycle to operate under drug treatment. This is
especially important when nucleic acid synthesis inhibi-
tors are targeting either branch of the pentose cycle,
the operation of these alternative synthesis routes is
essential for the survival of tumor cells and to endure
apoptosis inducing drugs and signals.
6. Future metabolic drug design scenarios based
on what we know already
Genetics and proteomics generated enough data in
the last two decades that targeted therapies against
unique genes and proteins are entering clinical practice
for the treatment of cancer. Signiﬁcant resistance to new
targeted therapies as a clinical problem appeared in a
rather quick and frequent manner, bringing new chal-
lenges back to the laboratory. As metabolic tracer data
accumulates and the operation of the transformed
metabolic network of tumor cells is slowly revealed, new
opportunities have arisen via metabolic targeted thera-
pies. The current challenges are several, ﬁrst of all more
data are needed and need to be correlated with tumor
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Figure 1. SIDMAP of apoptosis sensitive human cells. Red arrows
indicate routes of 13C tracer glucose substrate carbons (red ﬁlled
circles) in the metabolic network. The heavy use of glucose carbons via
the pentose cycle in human ﬁbroblasts (TRMA cells) is primarily via
the non-oxidative route, while the oxidative pathway is limited due to
low NADP–NADPH cycling and fatty acid synthesis. Black arrows
indicate less active pathways. Human ﬁbroblasts with high aﬃnity
thiamine transport deﬁciency readily undergo spontaneous apoptosis
(Boros et al., 2000b) and MIA PaCa show sensitivity and slow growth
to non-oxidative pentose cycle inhibitors (Boros et al., 1997).
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characteristics. Secondly, it is likely that metabolic tar-
geted therapies against tumors will have to be aimed at
multiple sites and control enzymes in the network due to
the fact that metabolic networks are interconnected and
alternative synthesis pathways are common (that is to
say a metabolic network exists). Thirdly, individual
SIDMAPs of tumor cells and host organs will likely help
tailoring metabolic targeted drugs to individual tumor
growth characteristics in the host. Based on what is
known so far, it can be predicted that limited de novo
fatty acid synthesis of a given tumor will allow pentose
cycle inhibitors to work eﬀectively, while tumors
possessing high rate of fatty acid turnover have to be
targeted with a combined approach using fatty acid
synthase, chain elongase and desaturase inhibitors,
along with conventional drugs targeting pentose cycle
synthesis, nucleic acid backbone sugar production,
RNA synthesis, DNA replication and consequently cell
proliferation. Tumor SIDMAPs can easily be deter-
mined both in vitro and in vivo, using non-invasive, non-
radiating and natural sugar tracers for both diagnostic
and metabolic targeting purposes.
7. Conclusions
As metabolic proﬁling allows new targets to be dis-
covered, their promise is that these targets will have
signiﬁcantly far less ﬂexibility and variability to escape
treatment than do genetic and signal protein targets.
This is based on the fact that structures of metabolic
enzymes and hierarchies of metabolic networks are well-
preserved throughout evolution and among species, and
tumor cells have to adhere to these hierarchies to sur-
vive. Regardless of the level of transformation and
malignancy, tumor cells have to integrate and co-ordi-
nate their metabolism with a complex host operating on
a limited number of substrates and co-operative futile
cycles. It is evident that mutations in growth signal
proteins make them hidden from drugs that target them
without losing function. Many growth signals exist
contemporarily, they initiate downstream eﬀects that
can become constitutively active (Boros, 2004) and they
can maintain signaling by variations in gene expression.
On the other hand, mutations in metabolic enzyme
proteins, although may also make them to escape newly
designed metabolic reaction targeting drugs, these
mutations will also make them non-functional and
defective to catalyze the metabolic reaction which the
inhibitor tends to control. Over-expression of metabolic
enzymes is rather a real threat to develop resistance
against metabolic targeted therapies and this is where a
combined approach of genomics, proteomics and met-
abolomics will change the future. The purpose of met-
abolomics in the new targeted era of drug design is to
pinpoint targets in the fundamental components of cell
function. These targets have very limited ﬂexibility and
variability to develop resistance by point mutations or
structural/conformational changes, or any other mech-
anism that make genetic and protein targets weak and
short-lived.
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